16 results about "Abdominal Infection" patented technology

The invention discloses a peritoneal drainage flushing device based on multi-dimensional parameter monitoring and a negative pressure regulation and control system, and belongs to the technical field of peritoneal drainage. The peritoneal drainage flushing device and negative pressure regulation and control system based on multi-dimensional parameter monitoring comprises a device support, a multi-channel rotary valve and two negative pressure pumps, a flow guide pipe and a backflow pipe are arranged between the two negative pressure pumps and the multi-channel rotary valve, and pipeline detection modules are installed on the flow guide pipe and the backflow pipe. The peritoneal drainage device solves the problems that an existing peritoneal drainage device is not ideal in treatment effect and affects the treatment effect when a drainage tube is blocked, early intervention is carried out by adjusting a negative pressure pump, a multi-channel rotary valve and a three-way electromagnetic valve, targeted treatment is automatically triggered at the early stage of complications through continuous and multi-dimensional monitoring, and the treatment effect is effectively improved. The tube blocking rate, the abdominal infection rate and the abdominal hypertension syndrome occurrence rate are remarkably reduced, the pain of a patient is relieved, the recovery time is shortened, and personalized and self-adaptive adjustment is carried out according to the physical state of the patient.

The invention discloses a lipidosome composite hydrogel microsphere for repairing damaged intestinal mucosa and a preparation method thereof, LHMs (at) 4-OI is composed of hyaluronic acid modified targeted drug-loaded lipidosome, sodium alginate, hydrochloric acid treated sucralfate and a CaCl cross-linking agent, and rapid gel forming is carried out under the voltage of 11.0 KV through an electrospray technology. The microspheres have pH responsiveness and gastric juice digestion resistance, CD44 receptor targeting is achieved through hyaluronic acid modification, sodium alginate and Ca form an egg box structure to provide a three-dimensional network, and sucralfate enhances adhesion to isolate harmful substances. The preparation method comprises the steps of preparation of the drug-loaded liposome by a film hydration method, hyaluronic acid modification and electrospray crosslinking, is simple to operate and low in cost, and can be used for large-scale production. The microspheres can effectively load an anti-inflammatory drug 4-OI, inhibit expression of inflammatory factors and promote self-repair of damaged intestinal mucosa, and have wide application prospects in the fields of abdominal infection, inflammatory bowel diseases, colorectal cancer and the like.

This invention provides a reusable ascites drainage device, comprising: a drainage seat, a drainage tube, a negative pressure assembly, and a collection container; one end of the drainage tube is connected to the drainage seat, and the negative pressure assembly and the collection container are both connected to the other end of the drainage tube; the negative pressure assembly is used to generate negative pressure within the drainage tube, allowing ascites fluid from the drainage seat to enter the drainage tube; the collection container is used to collect the ascites fluid draining from the drainage tube; the drainage seat includes an annular shell, one end of which is provided with a self-sealing soft body for sealing; one end of the drainage tube is connected to a puncture needle, which is inserted into and penetrates the self-sealing soft body into the annular shell. This embodiment reduces tissue damage from repeated punctures, improves patient comfort, enhances the precise control of negative pressure within the drainage tube, protects tissues near the drainage seat from damage, and reduces the risk of abdominal infection.

The application belongs to the field of pharmaceutical chemistry and medicine, and relates to a cephalosporin compound and its use in preparing antibacterial drugs. Specifically disclosed are the use of a cephalosporin compound, or a pharmaceutically acceptable salt thereof, or a medicine composition taking the cephalosporin compound as an effective active ingredient in preparing a medicine for preventing and treating gram-negative drug-resistant bacterial infections. The compound can irreversibly covalently bind to metal beta-lactamase, inhibit the hydrolysis of beta-lactam antibiotics, effectively reduce the minimum inhibitory concentration (MIC) value and the blood bacterial load of gram-negative drug-resistant bacteria in a mouse with abdominal infection, and can be combined with beta-lactam antibiotics such as meropenem to prepare a compound preparation for treating diseases such as infections caused by gram-negative drug-resistant bacteria.

The invention discloses an antibacterial peptide derived from an animal metagenome as well as a preparation method and application of the antibacterial peptide. Specifically, the amino acid sequence of the antibacterial polypeptide is as shown in any one of SEQ ID NO.1-55. The antibacterial polypeptide provided by the invention has a novel amino acid sequence, and in-vitro experiments prove that the antibacterial polypeptide has inhibitory activity on common pathogenic bacteria such as escherichia coli, salmonella, staphylococcus aureus or streptococcus. According to the invention, evaluation on multiple aspects such as minimum inhibitory concentration, biological safety (namely cytotoxicity and hemolysis effect on mammalian cells) and the like is carried out, and a mouse acute abdominal cavity infection model is established to verify the antibacterial activity of the antibacterial polypeptide in vivo. Results show that the antibacterial polypeptide shows high antibacterial activity in vitro and still keeps certain antibacterial activity in in-vivo experiments, and the survival rate of mice with acute abdominal infection can be increased.

The invention discloses a targeted B cell epitope peptide monoclonal antibody as well as a preparation method and application thereof, five B cell epitope peptide positive hybridoma cell strains: 2G6H3, 6F11B7, 6F11E4, 4H9D8 and 4H9B7 are successfully screened by utilizing a hybridoma cell technology, and the monoclonal antibody is purified. The five monoclonal antibodies can recognize B cell epitope peptide, rEm.P29 and P29 protein in natural antigen, and 6F11B7, 6F11E4 and 2G6H3 which are high in specificity and affinity are selected for evaluating the curative effect of an abdominal cavity infected animal model. The results show that the monoclonal antibody can significantly inhibit the growth of echinococcus multilocularis in mice, has a curative effect higher than that of a clinical drug albendazole, does not have side effects such as liver and kidney function impairment caused by chemotherapeutic drugs, and does not affect other organs. The invention has treatment potential and treatment safety, and provides a brand new treatment strategy for clinically treating the alveolar echinococcosis.

The application discloses synthesis of a novel Schiff base gold (III) compound and antibacterial application thereof, and belongs to the technical field of medicine preparation; gold sodium aurothiomalate has significant antibacterial activity, but the Au-S bond thereof is easily broken by intracellular reducing thiol, and the gold sodium aurothiomalate is metabolized before reaching a target point to produce toxic side effects; based on the gold sodium aurothiomalate, developing a gold compound with stronger stability is one of strategies for overcoming drug-resistant bacteria; the Schiff base itself has antibacterial activity, and after being combined with gold (III) ions, the Schiff base can stabilize gold atoms and improve the activity of the gold atoms; in vitro antibacterial activity shows that Au6 and Au13 have significant antibacterial advantages on carbapenem and polymyxin-resistant Klebsiella pneumoniae, the minimum inhibitory concentration (MIC) is 10 micromoles, and the antibacterial activity is at least 16 times higher than that of the gold sodium aurothiomalate; in vivo antibacterial activity experiments prove that Au6 and Au13 can reduce mouse skin infection and promote wound healing, and can prolong the survival time of abdominal infection mice, and have important practical application value.

The utility model discloses a sleeve type drainage tube fixing device which comprises a sleeve body, the two ends of the sleeve body are constraint ends, and after a drainage tube enters the sleeve body, the sleeve body is temporarily clamped on the drainage tube through the constraint ends. The drainage device is simple in structure and convenient to operate, the drainage tube placed in the drainage device can be continuously tightened through the tightening cap and the valve piece, the purpose of fixing and protecting the drainage tube is achieved, and the situation that a tube cavity is twisted and folded due to the change of the body position of a patient, the gravity action of the drainage device and the like is reduced; meanwhile, the joint of the inner tube and the outer tube and the exposed part of the inner tube are also protected, and secondary infection caused by hospital sexual infection to a patient is avoided.

The utility model relates to the technical field of puncture drainage, in particular to an anti-blocking abdominal cavity puncture drainage device. The problem that an existing drainage tube is blocked by impurities in the working process and cannot work normally is solved. Comprising a supporting pipe, the upper side of the supporting pipe is fixedly connected with a connecting shell, the interior of the supporting pipe is slidably connected with a drainage pipe, a pressure detector is arranged in the drainage pipe, one side of the supporting pipe is fixedly connected with a mounting shell, the lower side of the supporting pipe is fixedly connected with an impact pipe, and a water supply assembly is arranged in the mounting shell; the water supply assembly is used for supplying water into the impact pipe. According to the utility model, water sprayed from the impact holes in the impact tube impacts the water absorption holes, so that impurities blocked in the water absorption holes are cleaned, the normal work of the drainage tube is ensured, the abdominal cavity puncture drainage work is smoothly carried out, meanwhile, the abdominal cavity is prevented from becoming a hotbed for bacterial reproduction, and the risk of abdominal cavity infection is reduced.

The invention discloses a classification method and a classification device for abdominal cavity infectious effusion. The classification method comprises the following steps: segmenting a plurality of non-enhanced CT images by using a pre-trained segmentation model; for each liquid accumulation region, applying a morphological dilation operation of a first size to produce a first lesion surrounding region, and performing a morphological dilation operation of a second size to produce a second lesion surrounding region; extracting a quantitative morphological feature, a 3D radiomics feature, a plurality of focus surrounding features, a plurality of local pathological features and a plurality of global context features; selecting a plurality of target features, and calculating a radiomics score of each non-enhanced CT image; inputting the radiomics score and the clinical parameters into a logistic regression model for training to obtain a trained logistic regression model; and using the trained logistic regression model to classify non-enhanced CT images to be classified. According to the method, the classification of the infectious hydrops in the abdominal cavity can be quickly and accurately realized at low cost.

The utility model relates to an abdominal cavity drainage device with a flushing pipeline, which is characterized in that a drainage tube body (0) of the device is of a sandwich structure and consists of an outer tube (001), an inner tube (002) and a water injection cavity (102). The water injection inlet pipe (101) is communicated with the water injection cavity (102), the water injection notch (103) and the drainage notch (203) are respectively communicated with the water injection cavity (102) and the inner pipe (002), and the drainage outlet pipe (201) is connected with the inner pipe (002) and is connected with a liquid collection assembly containing a liquid collection bottle (303) and the like. During working, flushing liquid flushes the sinus tract through the water injection cavity (102), percolate flows into the inner tube (002) and then enters the liquid collecting assembly, and the flow intercepting clamp (302) can control flow of drainage liquid. Compared with the prior art, blood clots, necrotic tissues and pus in the sinus tract can be effectively removed, the risk of abdominal cavity infection caused by blockage of the drainage tube is greatly reduced, and good conditions are created for wound healing.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an antibacterial peptide KP5 in preparation of a medicine for treating carbapenem-resistant acinetobacter baumannii infection. The invention finds that the antibacterial peptide KP5 with the amino acid sequence shown as SEQ ID NO: 1 has obvious inhibitory activity on carbapenem-resistant acinetobacter baumannii for the first time, so that a brand new effective treatment means can be provided for clinically treating infection (especially acute abdominal infection) caused by drug-resistant bacteria. Moreover, the invention further finds that the antibacterial peptide KP5 and the acinetobacter baumannii infection resisting drug sulbactam can generate a synergistic effect when being used together under a specific concentration, and the synergistic effect can obviously enhance the antibacterial effect on carbapenem-resistant acinetobacter baumannii; an important basis is provided for optimizing a treatment scheme for resisting carbapenem acinetobacter baumannii infection.

The invention discloses a percutaneous puncture abdominal war trauma early-stage multifunctional first-aid kit which comprises a Trocar puncture assembly, a double sleeve, an outer connector, a flushing assembly, a liquid collecting bottle and a negative pressure pump, and the Trocar puncture assembly is used for puncturing the abdominal cavity of a patient; the double sleeve is matched with the Trocar puncture assembly, and the double sleeve is guided to be placed into an abdominal cavity infection part through the Trocar puncture assembly; the outer joint is mounted at the opening end of the double sleeve; the flushing assembly is connected with the outer connector through a flushing pipe and used for injecting normal saline into the double sleeves. The top of the liquid collecting bottle is connected with the outer connector through the drainage tube and used for being matched with the double sleeves to drain thick fester and necrotic tissue in the abdominal cavity of a patient and centralize the thick fester and the necrotic tissue in the liquid collecting bottle. The air inlet end of the negative pressure pump is connected with the top of the liquid collecting bottle through an air suction pipe and used for pumping air so that negative pressure can be formed in the space in the liquid collecting bottle. The side holes in the side faces of the drainage channels in the double sleeves cooperate with continuous negative pressure, and viscous pus and necrotic tissue can be effectively discharged.

Alcohol-associated liver disease, particularly alcohol-associated hepatitis, constitutes a significant global health burden with high mortality rates. Imbalances in the gut microbiota are important for the progression of alcohol-associated liver disease, a condition classified as non-infectious. Disclosed herein are methods of treating or ameliorating a symptom of alcohol-associated hepatitis and methods of reducing or preventing mortality associated with alcohol-associated hepatitis. Also disclosed herein are methods of treating or ameliorating a symptom of sepsis, urinary tract infection, pneumonia, intra-abdominal infections, and / or endocarditis. Further disclosed are methods of determining responsiveness of a subject to treatment with the small molecule inhibitor C7, methods of identifying a subject for a clinical trial for treatment for alcohol-associated hepatitis and methods of screening for candidate compounds for treating alcohol-associated hepatitis.

The application provides an abdominal cavity flushing and draining device, which comprises a draining tube, a flushing tube, a plug-in seat, an elastic sealing part, and the flushing tube is plugged into the inner cavity of the draining tube; the plug-in seat is arranged on the draining tube and is provided with a plug-in hole for inserting the flushing tube; the elastic sealing part is sleeved at the connection part of the draining tube and the flushing tube, one end of the elastic sealing part is in sealing connection with the plug-in seat, and the other end of the elastic sealing part is in sealing connection with the peripheral wall of the flushing tube; since the elastic sealing part is wrapped outside the flushing tube, the elastic sealing part blocks dust and bacteria in the outside world during the pulling process of the flushing tube, and the risk of abdominal cavity infection of a patient is reduced.

The application discloses a peritoneal cavity drainage and flushing device and a negative pressure regulation system based on multidimensional parameter monitoring, and belongs to the technical field of peritoneal cavity drainage. The peritoneal cavity drainage and flushing device and the negative pressure regulation system based on multidimensional parameter monitoring comprise a device support, a multi-channel rotary valve and two negative pressure pumps, a flow guide pipe and a backflow pipe are arranged between the two negative pressure pumps and the multi-channel rotary valve, and a pipeline detection module is installed on the flow guide pipe and the backflow pipe. The application solves the problems of the existing peritoneal cavity drainage device, such as blockage of a drainage pipe, unsatisfactory treatment effect and influence on treatment effect. The application realizes early intervention through adjustment of the negative pressure pump, the multi-channel rotary valve and a three-way electromagnetic valve, automatically triggers targeted treatment in the early stage of complications through continuous multidimensional monitoring, significantly reduces the pipe blockage rate, the peritoneal cavity infection rate and the incidence of peritoneal cavity hypertension syndrome, alleviates the pain of patients, shortens the recovery time, and realizes individualized and adaptive adjustment according to the body state of the patients.